Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Claire N. Harrison*, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Ramon V. Tiu, Pierre Zachee, Eric Jourdan, Elliott Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E317-E324
Number of pages8
JournalThe Lancet Haematology
Volume4
Issue number7
DOIs
Publication statusPublished - Jul 2017

Keywords

  • MYELOPROLIFERATIVE NEOPLASMS
  • AVAILABLE THERAPY
  • CLINICAL-TRIAL
  • MANAGEMENT
  • REVISION
  • JAK2

Cite this

Harrison, C. N., Schaap, N., Vannucchi, A. M., Kiladjian, J-J., Tiu, R. V., Zachee, P., Jourdan, E., Winton, E., Silver, R. T., Schouten, H. C., Passamonti, F., Zweegman, S., Talpaz, M., Lager, J., Shun, Z., & Mesa, R. A. (2017). Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. The Lancet Haematology , 4(7), E317-E324. https://doi.org/10.1016/S2352-3026(17)30088-1